More on ImClone's mystery bidder

The identity of ImClone's mystery bidder will be revealed tomorrow even if it does not make a final offer, the company said, as the Financial Times reported that the bidder was a U.S.-based drugmaker with "pipeline synergies" with its buyout target. Report | Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.